Canopy Growth Corp Dossier - Source-backed chat

Canopy Growth Corp

CGCNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)1.95

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $0.88Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $396.5M

Enterprise Value $300M

Shares Outstanding 449.3M diluted

Next Earnings Date6 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Canopy Growth Corp. has successfully executed a strategic reset in Fiscal Year 2026, significantly narrowing its net loss from continuing operations and improving its free cash flow profile. The completed acquisition of MTL Cannabis positions the company as Canada's leading medical cannabis provider by revenue, while a strategic recapitalization in January 2026 has extended debt maturities to 2031 and left the company with a net cash position of C$131.3 million. However, persistent profitability challenges, a material weakness in internal controls over financial reporting, and ongoing regulatory uncertainties in both Canadian and international markets warrant a cautious Hold recommendation until positive Adjusted EBITDA is consistently achieved.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$1.23

Mean target$1.23

High · most bullish analyst$1.23

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Integration challenges with MTL Cannabis or prolonged supply chain disruptions in Europe limit revenue growth. The company fails to achieve positive Adjusted EBITDA in FY2027, leading to continued cash burn and further shareholder dilution through at-the-market equity programs.

Base CaseCentral scenario

The company successfully integrates MTL Cannabis, driving sequential gross margin improvements in the Canadian adult-use and medical segments. Cost-saving initiatives and optimized operations lead to positive Adjusted EBITDA during Fiscal Year 2027, while the balance sheet remains stable with extended debt maturities.

Bull CaseUpside scenario

Canopy Growth's bull case centers on its successful operational turnaround, cost-reduction efforts, and strategic positioning for regulatory shifts. Key drivers include: (1) Achieving positive adjusted EBITDA, guided by management for fiscal 2027, supported by narrowing losses and a full reset around cost discipline. (2) Core cannabis top-line growth, driven by double-digit gains in Canadian adult-use, medical, and international cannabis revenue. (3) Strategic acquisitions, notably MTL Cannabis, which establishes Canopy as the largest medical cannabis provider in Canada by revenue and strengthens its balance sheet to a net cash position. (4) Potential U.S. federal regulatory catalysts, such as DEA rescheduling, which would facilitate the consolidation of its U.S. ecosystem (Canopy USA) and eliminate punitive Section 280E tax burdens.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Market leadership in the Canadian medical cannabis segment by revenue following the MTL Cannabis acquisition.
Strengthened balance sheet with C$131.3 million in net cash and debt maturities extended to 2031.
Significant optionality in the U.S. THC market through Canopy USA, LLC, poised to benefit from potential federal rescheduling.
Strong international footprint, highlighted by the relaunch of the Tweed brand in Germany with MTL-derived strains.

Key Investment Risks

History of persistent net losses and negative cash flows from continuing operations.
Material weakness in internal control over financial reporting identified as of March 31, 2026.
High cost of capital and potential for ongoing shareholder dilution from equity issuance programs.
Intense competition and pricing pressure in the Canadian adult-use cannabis market.

Thesis Invalidation Triggers

Failure to achieve positive Adjusted EBITDA during Fiscal Year 2027.
Unexpected regulatory setbacks or delays in U.S. cannabis rescheduling.
Significant write-downs or operational disruptions related to the integration of MTL Cannabis.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.